A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer

Gemcitabine plus nab-paclitaxel (GnP) is widely used in clinical practice, despite a lack of prospective data to validate its efficacy in locally advanced pancreatic cancer (LAPC). We conducted a phase II study of GnP for LAPC to assess its efficacy and safety. We performed a single-arm, single-inst...

Descripción completa

Detalles Bibliográficos
Autores principales: Fukahori, Masaru, Miwa, Keisuke, Murotani, Kenta, Naito, Yoshiki, Ushijima, Tomoyuki, Sakaue, Takahiko, Tanaka, Toshimitsu, Nagasu, Sachiko, Suga, Hideya, Kakuma, Tatsuyuki, Okabe, Yoshinobu, Torimura, Takuji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137062/
https://www.ncbi.nlm.nih.gov/pubmed/34011119
http://dx.doi.org/10.1097/MD.0000000000026052

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8137062/
https://www.ncbi.nlm.nih.gov/pubmed/34011119
http://dx.doi.org/10.1097/MD.0000000000026052

Ejemplares similares